• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Namenda: Pining for Another Indication

Namenda: Pining for Another Indication

August 1, 2005
Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue
Daniel Carlat, MD Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
In 2003, the FDA approved Namenda (memantine) as a treatment for moderate to severe Alzheimer’s Dementia (AD). Backed by the legendary marketing expertise of Forest Labs, the medication has become remarkably popular, gradually eating into the market share of the cholinesterase inhibitors (CIs). The question, as always, is whether this popularity is justified by the data.

Recently, a meta-analysis was published by the Cochrane Collaborative reviewing pretty much everything that we know about Namenda to date (http://www.mrw.interscience.wiley. com/cochrane/clsysrev/articles/CD003154/frame.html, accessed 6/30/05), including nine published and three unpublished studies. For those who don’t know, the Cochrane reviews are considered the international “gold standard” in evidence-based health information.

Let’s look first at how robust the data is for Namenda’s only official FDA indication, moderate to severe Alzheimer’s dementia. The standard research definition of “moderate to severe dementia” is an MMSE score below 15; in the two Namenda studies, the average MMSE of participants ranged from 8 to 10 (NEJM, 2003; 348:1333-1341, and JAMA, 2004; 291:317-324). This is a level of impairment that most of us are unlikely to see in our offices, unless we specialize in dementia treatment. According to the study authors, these patients typically required assistance with basic ADLs, such as bathing and dressing, and many were incontinent.

In this population, Namenda 20 mg QD was statistically superior to placebo in measures of cognition, ADLs, and agitation, but the effect sizes, in all cases, were “small or very small,” according to the reviewers. The primary cognitive measure in these studies, the “SIB,” is a scale ranging in score from 0-100; the average improvement over placebo in the two trials was 4 SIB points, unlikely to yield a clinically significant improvement, particularly in such an impaired population.

There also exists a mysterious third Namenda study, named “MD-01” by Forest, but it hasn’t yet been published, even though the study was completed in June of 2003. Such a long lag in study publication is generally diagnostic of unfavorable results, leading the Cochrane reviewers to conclude that the published results may overestimate the effectiveness of Namenda (this phenomenon is known as “publication bias”). TCR urges you to nudge your Forest reps about the MD-01 results next time you see them!

What about Namenda for mild to moderate dementia? Just as we were about to go to press with this issue, Forest announced that the FDA rejected Namenda’s application for approval for mild dementia, which was no surprise to those who had looked at the data. No studies of Namenda for mild to moderate AD have been published. One study, presented as a poster, showed a small benefit over placebo, but the two other studies yielded no significant effects, according to the Cochrane review.

Data or not, Forest has found a creative way to produce a mild-dementia “halo effect” around Namenda. They did this by funding a study in which 404 patients with moderate to severe AD, all of whom had been taking Aricept for about two years, were randomized to receive add-on Namenda vs. add-on placebo. The Namenda group did a little bit better than the placebo group after six months (JAMA, 2004; 291:317-324). While Forest can officially use this study only to promote Namenda for moderate to severe AD, the fact that it was added to a drug only approved for mild to moderate AD (Aricept) has the effect of planting a seed in our minds that Namenda might be effective for both indications. Talk about subliminal advertising!

TCR VERDICT: Namenda: A small effect for the most impaired.
General Psychiatry
Carlat 150x150
Daniel Carlat, MD

20 Years of The Carlat Report

More from this author
www.thecarlatreport.com
Issue Date: August 1, 2005
SUBSCRIBE NOW
Table Of Contents
The Man Behind Alzheimer’s Disease
Marc Agronin, M.D., on Treating Agitation in Dementia
Rosack’s FDA Watch: Atypical Antipsychotics and the Elderly
Namenda: Pining for Another Indication
Cholinesterase Inhibitors: Under Siege
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto11543850.jpg
    General Psychiatry

    Elvis, Adderall, and a Broken Heart - Part 1

    A new medical investigation changes our understanding of Elvis Presley’s untimely death and offer some pearls for modern psychiatric practice.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.